Home > News > Headline News > Archive

Click on title to read the full article.

Elizabeth Edward's Cancer

December 11, 2010

By Ellen Moskowitz

Elizabeth Edwards remains a hero in the metastatic community. She gave a face, her face, to metastatic breast cancer. She let the world know that she was living with a terminal diagnosis.

Combination therapy with everolimus may improve metastatic breast cancer outcomes

December 10, 2010

By T. Batchelot

Everolimus plus tamoxifen yielded clinical benefit rates nearly 20% higher than those observed for tamoxifen alone in women with hormone receptor-positive, HER-2–negative metastatic breast cancer, according to findings presented here at the 33rd Annual San Antonio Breast Cancer Symposium.

Lessons From Elizabeth Edwards

December 8, 2010

By Barron H. Lerner MD

The news that Elizabeth Edwards died on Tuesday is extremely sad. Ms. Edwards, 61, a lawyer, mother and author of two autobiographical books and the estranged wife of former Senator John Edwards, had only recently announced that she had stopped treatment for advanced breast cancer.

Opinion: Disallowing cancer drug would set a terrible precedent and cost lives

December 7, 2010

By Peter J. Pitts

The Food and Drug Administration is about to render a ruling that could change the lives of countless breast cancer sufferers. On Dec. 17, the agency will decide whether to allow the biologic drug Avastin to be used in the treatment of metastatic breast cancer -- the most advanced stage of the disease.

Biopsy needed to confirm switched biomarker status between primary, recurrent breast cancer

December 3, 2010

By Thompson AM. Breast Cancer Research

Mounting evidence exists that patients with relapsed breast cancer should undergo confirming tissue sampling to identify changes in biomarker status that might influence disease treatment. According to background information of the retrospective Breast Recurrence in Tissues Study – or BRITS – historically, ER, PR, and HER2 status taken from the primary cancer were used to direct treatment upon recurrence; however, this approach is no longer considered appropriate. Instead, new tissue should be tested upon disease recurrence, the researchers wrote.

 < 1 2